Literature DB >> 23253944

Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia.

Natalie Matosin1, Kelly A Newell.   

Abstract

Metabotropic glutamate receptor 5 (mGluR5) potentiates the NMDA receptor (NMDAR) in brain regions implicated in schizophrenia, making it a viable therapeutic target for the treatment of this disorder. mGluR5 positive allosteric modulators may represent a valuable novel strategy for schizophrenia treatment, given the favourable profile of effects in preclinical paradigms. However it remains unclear whether mGluR5 also plays a causal or epiphenomenal role in NMDAR dysfunction in schizophrenia. Animal and cellular data suggest involvement of mGluR5, whilst post-mortem human studies remain inconclusive. This review will explore the molecular, animal and human data to support and refute the involvement of mGluR5 in the pathology of schizophrenia. Furthermore, this review will discuss the potential of mGluR5 modulators in the therapy of schizophrenia as well as aspects of mGluR5 that require further characterisation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23253944     DOI： 10.1016/j.neubiorev.2012.12.005

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN： 0149-7634            Impact factor:   8.989


  33 in total

Review 1.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

2.  Increased Metabotropic Glutamate Receptor 5 Signaling Underlies Obsessive-Compulsive Disorder-like Behavioral and Striatal Circuit Abnormalities in Mice.

Authors:  Kristen K Ade; Yehong Wan; Harold C Hamann; Justin K O'Hare; Weirui Guo; Anna Quian; Sunil Kumar; Srishti Bhagat; Ramona M Rodriguiz; William C Wetsel; P Jeffrey Conn; Kafui Dzirasa; Kimberly M Huber; Nicole Calakos
Journal:  Biol Psychiatry       Date:  2016-05-13       Impact factor: 13.382

3.  Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.

Authors:  Jerri M Rook; Zixiu Xiang; Xiaohui Lv; Ayan Ghoshal; Jonathan W Dickerson; Thomas M Bridges; Kari A Johnson; Daniel J Foster; Karen J Gregory; Paige N Vinson; Analisa D Thompson; Nellie Byun; Rebekah L Collier; Michael Bubser; Michael T Nedelcovych; Robert W Gould; Shaun R Stauffer; J Scott Daniels; Colleen M Niswender; Hilde Lavreysen; Claire Mackie; Susana Conde-Ceide; Jesus Alcazar; José M Bartolomé-Nebreda; Gregor J Macdonald; John C Talpos; Thomas Steckler; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  Neuron       Date:  2015-04-30       Impact factor: 17.173

Review 4.  Location-dependent signaling of the group 1 metabotropic glutamate receptor mGlu5.

Authors:  Yuh-Jiin I Jong; Ismail Sergin; Carolyn A Purgert; Karen L O'Malley
Journal:  Mol Pharmacol       Date:  2014-10-17       Impact factor: 4.436

Review 5.  Regulation and Function of Activity-Dependent Homer in Synaptic Plasticity.

Authors:  Nicholas E Clifton; Simon Trent; Kerrie L Thomas; Jeremy Hall
Journal:  Mol Neuropsychiatry       Date:  2019-05-23

6.  Chronic Adolescent CDPPB Treatment Alters Short-Term, but not Long-Term, Glutamatergic Receptor Expression.

Authors:  Jeremy S Lum; Samuel J Millard; Elisabeth Frank; Natalie Matosin; Xu-Feng Huang; Lezanne Ooi; Kelly A Newell
Journal:  Neurochem Res       Date:  2018-06-23       Impact factor: 3.996

7.  Trisubstituted imidazoles as positive modulators of metabotropic glutamate receptor subtype 5.

Authors:  Gerard Rosse
Journal:  ACS Med Chem Lett       Date:  2013-08-06       Impact factor: 4.345

8.  Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4).

Authors:  Rocco D Gogliotti; Anna L Blobaum; Ryan M Morrison; J Scott Daniels; James M Salovich; Yiu-Yin Cheung; Alice L Rodriguez; Matthew T Loch; P Jeffrey Conn; Craig W Lindsley; Colleen M Niswender; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2016-05-11       Impact factor: 2.823

Review 9.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

Review 10.  Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.

Authors:  Rajapillai L I Pillai; Dnyanesh N Tipre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.